Portal Hypertension - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 69
Inquire Before Buying

Global Markets Direct's, ‘Portal Hypertension - Pipeline Review, H2 2016', provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Portal Hypertension

  • The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects

  • The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Portal Hypertension

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Portal Hypertension - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Portal Hypertension Overview 6
Therapeutics Development 7
Pipeline Products for Portal Hypertension - Overview 7
Portal Hypertension - Therapeutics under Development by Companies 8
Portal Hypertension - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Portal Hypertension - Products under Development by Companies 11
Portal Hypertension - Companies Involved in Therapeutics Development 12
Conatus Pharmaceuticals Inc. 12
Cumberland Pharmaceuticals, Inc. 13
Galectin Therapeutics, Inc. 14
Genextra S.p.a. 15
LinXis B.V. 16
Mezzion Pharma Co. Ltd. 17
Portal Hypertension - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
emricasan - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
GRMD-02 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ifetroban sodium - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
LIN-003 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
obeticholic acid - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
udenafil - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Portal Hypertension - Dormant Projects 60
Portal Hypertension - Discontinued Products 61
Portal Hypertension - Product Development Milestones 62
Featured News & Press Releases 62
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 62
ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis 62
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 64
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 65
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 65
Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Number of Products under Development for Portal Hypertension, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 12
Portal Hypertension - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016 13
Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016 14
Portal Hypertension - Pipeline by Genextra S.p.a., H2 2016 15
Portal Hypertension - Pipeline by LinXis B.V., H2 2016 16
Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Portal Hypertension - Dormant Projects, H2 2016 60
Portal Hypertension - Discontinued Products, H2 2016 61

List of Figures

Number of Products under Development for Portal Hypertension, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Top 10 Targets, H2 2016 19
Number of Products by Stage and Top 10 Targets, H2 2016 19
Number of Products by Top 10 Mechanism of Actions, H2 2016 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 […]
  • Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021
    Published: 12-Apr-2017        Price: US 3500 Onwards        Pages: 70
    PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult. The analysts forecast global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021. Covered in this report This report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market siz......
  • EMEA (Europe, Middle East and Africa) Nitrendipine Market Report 2017
    Published: 10-Apr-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the EMEA Nitrendipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Nitrendipine for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; - Middle Ea......
  • United States Nitrendipine Market Report 2017
    Published: 31-Mar-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Nitrendipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Nit......
  • Global Nifedipine Sales Market Report 2017
    Published: 30-Mar-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global Nifedipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Nifedipine for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast ......
  • Global Captopril API Sales Market Report 2017
    Published: 30-Mar-2017        Price: US 4000 Onwards        Pages: 110
    In this report, the global Captopril API market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Captopril API for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - So......
  • Global Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2017
    Published: 30-Mar-2017        Price: US 2900 Onwards        Pages: 105
    In this report, the global Pulmonary Arterial Hypertension (PAH) Medicine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Medicine in these regions, from 2012 to 2022 (forecast), covering ......
  • Global Hypertension Partnering 2010 to 2017
    Published: 01-Mar-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the hypertension partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals......
  • Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Idiopathic (Essential) Hypertension Report is to understand the market and pipeline status of the drugs around the Idiopathic (Essential) Hypertension to explore the generic development opportunities, li......
  • Resistant Hypertension-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Resistant Hypertension-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Resistant Hypertension. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs